NTRK1 and neoplasm: Mechanistic data across tumor-cell, endothelial, neuronal and myeloid compartments support therapeutic interrogation of these axes, with fusion-directed TRK inhibition as standard of care where applicable and biomarker-guided investigation of pathway blockade in the broader population.